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Background: Murine studies suggest a beneﬁcial effect of systemic adiponectin on
asthma. Our objective was to determine the association between serum adiponectin
concentrations and asthma control/severity outcomes in men and women separately.
Methods: Cross-sectional and longitudinal analyses of data from years 10, 15, and 20
examinations of the prospective coronary artery risk development in young adults study
in the United States were performed. Asthma was deﬁned by self-reported provider diag-
nosis at or prior to year 15 examination. Outcomes included presence of active disease,
number of respiratory symptoms, and number of asthma medications; as well as longitu-
dinal decline in absolute FEV1.Year 15 serum adiponectin concentration was the predictor
variable. Results: In a multivariable analysis of 411 eligible subjects, after adjusting for body
mass index and covariates, higher serum adiponectin concentrations were associated with
more frequent active disease (including more frequent use of any asthma medication), and
greater number of respiratory symptoms and asthma medications among men but not
among women with asthma (p for interactions between sex and adiponectin for all analy-
ses< 0.05).Conclusions:Higher serum adiponectin concentrationsmay be independently
associated with adverse clinical outcomes of asthma in men but not in women. If biological
effect is conﬁrmed in future studies, modiﬁcation of systemic adiponectin concentrations
may open up newer ways to treat asthma in men.
Keywords: asthma control and severity, obesity, sex differences, serum adiponectin
INTRODUCTION
Adipokines, proteins produced by adipose tissue, may regulate
systemic inﬂammation and play a role in asthma (Sood et al.,
2006, 2008). Adiponectin is one such adipokine with predomi-
nantly anti-inﬂammatory effects (Kumada et al., 2004; Wulster-
Radcliffe et al., 2004). Recent studies suggest that adiponectin
may also have potential pro-inﬂammatory effects, as in the syn-
ovial tissue of patients with arthritis where it induces interleukin
(IL)-6 and matrix metalloproteinase-1 secretion (Ehling et al.,
2006).
Although visceral adipocytes are the most important source
of adiponectin, serum adiponectin concentrations are reduced in
obese subjects. This may be explained by hypoxia-related necro-
sis of adipocytes in obese subjects, resulting in activation of
macrophages (Cinti et al., 2005). These activated macrophages
produce tumor necrosis factor-alpha (TNF-α) and IL-6 which
Abbreviations: BMI, body mass index; CARDIA, coronary artery risk development
in young adults; FEV1, forced expiratory volume in one second; FVC, forced vital
capacity;HMW,high-molecular weight;HOMA,homeostasismodel assessment; IL,
interleukin; SAS, Statistical Analysis Software; TNF-α, tumor necrosis factor-alpha;
YALTA, young adult longitudinal trends in antioxidants.
in turn may inhibit the local production of adiponectin in a
paracrine fashion (Bruun et al., 2003). Adiponectin and all of its
known receptors are expressed in the lung (Miller et al., 2009).
Adiponectin is primarily transported from blood into the alveolar
lining ﬂuid via the T-cadherin molecule on the endothelium (Hug
et al., 2004).
The causative role of low adiponectin in lung disease has
been better established in mice than in humans. A study of lean
(BALB/cJ) mice of both sexes suggests that exogenous adminis-
tration of adiponectin attenuates allergen-induced airway hyper-
reactivity and eosinophilic inﬂux (Figure 1; Shore et al., 2006).
Genetically induced adiponectin deﬁciency in the lungs of normal-
weight mice results in increased expression of TNF-α in alveolar
macrophages (Summer et al., 2008). Although human data remain
inconclusive, a cross-sectional study shows that higher serum
adiponectin concentrations may be associated with decreased risk
for asthma in women (Sood et al., 2008). It is however not known
if serum adiponectin affects asthma control/severity outcomes in
adults.
The objective of this study was to assess whether serum
adiponectinwas associatedwith asthma control/severity outcomes
in men and women separately. If systemic adiponectin affects
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FIGURE 1 | A schematic representation of the suggested role of
adiponectin in murine asthma, based on work by Shore et al. (2006).
asthma control/severity outcomes, measures that modify it may
lead to newer therapies to treat subjects with asthma.
MATERIALS AND METHODS
STUDY DESIGN
Cross-sectional and longitudinal analyses of data from years 10,
15, and 20 examinations of the coronary artery risk development
in young adults (CARDIA) cohort and its young adult longitu-
dinal trends in antioxidants (YALTA) ancillary study were per-
formed. During 1985–1986, CARDIA randomly recruited 5,115
participants from geographically based populations in Birming-
ham, AL, USA, Chicago, IL, USA, and Minneapolis, MN, USA
by telephone or door-to-door, and from the membership of the
Kaiser-Permanente Health Plan in Oakland, CA,USA. About 50%
of those invited participated in the study. At year 0 examina-
tion, the study included participants aged 18–30 years (mean age
24.9± 3.7 years.) with approximately equal numbers who were
black and white, men and women, and high school graduates
and dropouts. Follow-up examinations were completed 2, 5, 7,
10, 15, and 20 years later. 3,950, 3,672, and 3,549 persons were
respectively examined at years 10, 15, and 20 examinations, con-
stituting 78%, 74%, and 72% respectively of the survivors from
the baseline cohort. Detailed methods, instruments, and qual-
ity control procedures are described at the CARDIA website
(http://www.cardia.dopm.uab.edu/ex_mt.htm) and in other pub-
lished reports (Hughes et al., 1987; Friedman et al., 1988). While
CARDIA is not strictly representative of an identiﬁable geographic
population, it is clearly highly relevant to U.S. populations of
young urban and suburban whites and blacks.
INCLUSION AND EXCLUSION CRITERIA
We included all participants with asthma at CARDIA year 15
examination who also had complete data for serum adiponectin,
body mass index (BMI), respiratory symptoms, and covariates, as
described below. Asthma was deﬁned as a self-report of a doctor
or nurse diagnosis of asthma at any of the years 0, 2, 5, 7, 10, or 15
examinations. Pregnant women, those not fasting for 8 h, or those
with missing data at year 15 were excluded.
STUDY MEASUREMENTS
Self-reported information was obtained by trained interviewers
using standardized questionnaires. Menopause was deﬁned by the
absence of menstrual periods for the previous 12months without
a speciﬁc cause. Pre-menopausal women were deﬁned as experi-
encing regular menstrual cycles for at least half the time over the
previous 12months, excluding times on birth control pills, preg-
nant or nursing. Height and weight was measured by trained tech-
nicians using standardized equipment with participants wearing
light clothing without shoes, and BMI was calculated.
Morning blood samples after at least 8 h of fasting were col-
lected from seated participants – tourniquet use was limited to
2min to prevent hemoconcentration. Samples were then cen-
trifuged, aliquoted, and frozen at −70˚C within 90min of the
collection. Total adiponectin was measured in serum as part of the
YALTA ancillary study by radioimmunoassay technique at Linco
Research, Inc. (St. Charles,MO,USA) using a polyclonal antibody
raised in a rabbit and puriﬁed recombinant adiponectin stan-
dards with an effective range of 0.2–40mg/L (Cnop et al., 2003).
Correlation between serum adiponectin concentrations measured
in blinded repeat samples from 407 subjects was 0.91 and the
inter-assay coefﬁcient of variation for our laboratory was 8.8%.
Prebronchodilator spirometry was performed at year 10 using
a Collins Survey 8-liter water sealed spirometer and an Eagle II
Microprocessor (Warren E. Collins, Inc., Braintree, MA, USA). At
year 20, a dry rolling-seal OMI spirometer (Viasys Corp, Loma
Linda, CA, USA) was used. No spirometry data were collected at
year 15 and therefore year 20 spirometry data were used in lieu of
year 15 data. A comparability study performed on 25 volunteers
demonstrated excellent consistency without systematic differences
between the old and new machines; the average difference being
6mL for forced vital capacity (FVC) and 21mL for FEV1. Standard
spirometry quality control and testing procedures were followed
at all examinations (American Thoracic Society, 1995;Miller et al.,
2005).
OUTCOME AND PREDICTOR VARIABLES
Asthma control and severity is a complex outcome that is difﬁcult
to deﬁne well (Reddel et al., 2009). Existing clinical scales focus
on three domains – respiratory symptoms, asthma medication
use and pulmonary function. However, these scales are not eas-
ily adapted to population-based research where access to detailed
clinical information is usually not available (Ungar et al., 2002;
Reddel et al., 2009). Surrogate outcome variables for each of the
three domains were therefore used. These included clinical out-
comes such as presence of active disease as deﬁned below (and
its component, namely the use of any asthma medication); num-
ber of respiratory symptoms; and number of asthma medications
used at year 15 examination; as well as physiological outcomes
such as longitudinal decline in absolute prebronchodilator FEV1
between years 10 and 20. The primary predictor variable for all
analyzes was year 15 serum adiponectin concentration. The time
axis for measurement of various predictor and outcome variables
is depicted in Figure 2.
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FIGURE 2 | Selected time axis for measurement of various outcome and predictor variables in the CARDIA study.
Active disease, a composite variable involving asthma symp-
toms and medications, was deﬁned as a subject report of either
taking a validated asthma medication at the time of examination
or of symptoms of asthma during the 1-year period prior to the
examination. Further, use of any asthma medication and number
of asthmamedications used are correlated with asthma severity in
population-based research (Ungar et al., 2002). For our analyses,
the need for asthmamedication was equated with report of taking
the medication under a prescription. Asthma medications stud-
ied included short and long-acting inhaled and oral β2 agonists,
inhaled and oral corticosteroids, leukotriene receptor antagonists,
theophylline, anticholinergic inhalers, and immunotherapy – the
daily dose of inhaled corticosteroidwas however not obtained.Val-
idation of medication use was performed by direct examination
of medication by trained study personnel.
The number of respiratory symptoms was obtained from cod-
ing the following seven questions with binary responses: (1) Does
your chest ever sound wheezy or whistling when you have a cold?
(2) Does your chest sound wheezy or whistling occasionally apart
froma cold? (3)Have you ever had an attack of wheezing thatmade
you feel short of breath? (4) Have you had two or more episodes
of attacks of wheezing that made you feel short of breath? (5) Are
you troubled by shortness of breath when hurrying on the level or
walking up a slight hill? (6)When walking on level ground, do you
have to walk slower than people your age because of breathless-
ness? and (7) Do you ever have to stop for breath when walking at
your own pace on level ground?
In addition to the above clinical measures, longitudinal change
in absolute FEV1 between years 10 and 20 examinations was
also analyzed. This outcome is associated with changes in most
other asthma outcome measures and may be a marker for airway
remodeling (Covar et al., 2004; Reddel et al., 2009).
STATISTICAL METHODS
Serum adiponectin concentration was studied as a continu-
ous variable after logarithmic transformation that yielded nor-
mal distribution of adiponectin with effects on categorical and
continuous outcomes being approximately linear. BMI was also
used as a continuous variable. Odds ratios from logistic regression
were used for categorical outcomes (i.e., presence of active disease
and use of any asthma medication). Slope estimates from Poisson
regression were used for count outcomes (number of respira-
tory symptoms and number of asthma medications used) using
Statistical Analysis Software (SAS) proc genmod and rate ratios
corresponding to the slope parameters were calculated. The distri-
bution of these outcomes was approximately Poisson distributed.
Estimates of longitudinal change in lung function were further
obtained from general linear model using SAS proc glm. The
change in lung function was approximately normally distributed.
Given the possible difference in adiponectin effect between men
and women (Sood et al., 2008), we performed formal tests for sex
interaction in the whole group and further examined subgroups
deﬁned by sex.
Covariates included in all models as a block were self-reported
smoking status, race (blacks vs. whites), and age – all measured
at year 15 examination. Smoking was treated as a categorical
variable, including current, former, and never smokers. Diabetes
mellitus, insulin resistance [deﬁned by the homeostasis model
assessment (HOMA)], and physical activity level (based upon the
questionnaire-assessed physical activity history score) were not
included since they were not noted to contribute signiﬁcantly to
these models, using stepwise regression. SAS (9.1.3, Cary, NC,
USA) was used. A two-sided p value of <0.05 was considered
statistically signiﬁcant.
All subjects gave informed consent for their participation in the
study. This study was approved by the Institutional Review Boards
at University of New Mexico, Albuquerque, NM, USA and at each
of the CARDIA study sites.
RESULTS
DEMOGRAPHIC CHARACTERISTICS
Of the 3,672 subjects in the CARDIA cohort at year 15 examina-
tion, 468 subjects had asthma, of which 411 subjects (258 women
and 153 men) had complete additional data (see Figure 3). Of
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FIGURE 3 | Flowchart of subject inclusion.
these 411 eligible subjects, 314 subjects (201 women and 113
men) additionally had complete spirometry data and 248 (171
women and 77 men) had active disease. Further, a review of val-
idated medication use showed that 66.1% of those with active
disease were using at least one asthma medication (mean number
and SD of asthma medications used were 1.1± 1.1) and 27.8%
were using inhaled corticosteroids. Therefore, most subjects in
this study were presumed to have asthma of “intermittent” or
“mild persistent” severity (National Heart Lung and Blood Insti-
tute, 2007a). As reported previously (Hankinson et al., 1999; Sood
et al., 2008; Nagel et al., 2009), women with asthma had greater
BMI, serum adiponectin concentrations, and FEV1/FVC percent
than men with asthma (Table 1).
SERUM ADIPONECTIN IS ASSOCIATED WITH ADVERSE CLINICAL
OUTCOMES OF ASTHMA IN MEN BUT NOT IN WOMEN
Among men with asthma, higher serum adiponectin concentra-
tions were associated with greater odds of having active disease,
using any asthmamedication, havingmore respiratory symptoms,
and using more asthma medications, after adjusting for block
covariates and BMI (Table 2). Interactions between sex and serum
adiponectin were signiﬁcant for each of the above outcomes in the
multivariable analyses, conﬁrming that these associations differed
between men and women with asthma.
Among women with asthma, higher serum adiponectin con-
centrations were thus associated with lower odds of having active
disease, although this association did not reach signiﬁcance in the
Table 1 | Distribution of selected demographic characteristics among
women and men with asthma.
Characteristics Women (n=258) Men (n=153)
Age (in years) 40.3±3.6 40.0±3.6
Race (% whites) 46.1 54.3
Low annual household income
(%, <$25,000)
20.7 14.4
Low educational status (%,
≤high school graduate)
23.0 22.7
Lack of coverage for medical
care (%)†
11.3 19.7
Difﬁcult access to medical care
(%)
12.1 11.3
Current smokers (%)† 19.4 22.2
History of diabetes mellitus
(%)†
10.3 4.0
Insulin resistance (HOMA units) 2.8 (2.6, 3.1) 2.6 (2.4, 2.9)
Physical activity (in exercise
units)†
171.1
(149.6, 195.8)
298.5
(248.9, 358.0)
Body mass index (in kg/m2)† 31.7±9.0 28.5±5.8
Serum adiponectin
concentration (mg/L)†
10.0 (9.3, 10.8) 7.3 (6.7, 8.0)
Number of respiratory
symptoms†
3.6±1.8 3.0±1.8
Active asthma (%)† 66.3 50.3
Number of respiratory
symptoms*
4.1±1.7 3.9±1.6
Asthma medication use (%)* 63.2 72.7
Inhaled corticosteroid use (%)* 25.2 33.8
Number of asthma medications
used*
1.0±1.0 1.3±1.3
Percent FEV1/FVC ratio at year
10†
78.2±7.2 73.3±9.4
Percent predicted FEV1 at year
10†
94.9±14.9 88.5±15.6
Percent FEV1/FVC ratio at year
20†
77.2±7.3 72.4±10.0
Percent predicted FEV1 at year
20
89.3±15.5 86.0±17.3
Ten-year (years 20–10) change
in absolute FEV1 (mL)
341±273 321±296
All data is measured at CARDIA year 15 examination unless otherwise indicated.
Data is presented as mean±SD. Geometrical mean is presented with 95% CI
in parentheses. Lung function data is presented from a subset of 314 partici-
pants (201 women and 113 men) with asthma. Race-speciﬁc equations from the
Third National Health and Nutrition Examination Survey were used to obtain pre-
dicted values for FEV1. †Comparisons between men and women with asthma
signiﬁcant at p value<0.05. *Analysis was performed in the subgroup of 248
participants (171 women and 77 men) with active asthma. HOMA, homeostasis
model assessment; FEV1, forced expiratory volume in one second; FVC, forced
vital capacity.
multivariable analysis. Although women showed no associations
between serum adiponectin and other measures of clinical out-
comes, these associations were different from men with asthma.
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Additionally, among pre-menopausal womenwith asthma, similar
effects were seen as among all women with asthma.
DIRECTION OF ASSOCIATION IS THAT ADIPONECTIN AFFECTS ASTHMA
IN MEN (LONGITUDINAL ANALYSES)
Additional longitudinal analyses were performed to evaluate the
direction of the association between asthma outcomes measures
at year 20 and 15 serum adiponectin concentrations. These results
(in Table 3) show the same direction of association as those
described in Table 2. Further, we did not ﬁnd either prevalent
asthma or inhaled corticosteroid use at year 10 examination to
predict serum adiponectin concentration at year 15. These analy-
ses suggest that adiponectin affects asthmaoutcomes inmen rather
than the reverse direction.
BMI IS ASSOCIATED WITH ADVERSE CLINICAL OUTCOMES OF ASTHMA
IN WOMEN BUT NOT IN MEN
Amongmenwith asthma,BMIwas not associatedwith any clinical
outcomes of asthma (Table 4). In contrast, higher BMI was asso-
ciated with greater odds of having active disease, using any asthma
medication, having more respiratory symptoms, and using more
asthma medications among women with asthma, after adjusting
for block covariates and serum adiponectin concentrations. Inter-
actions between sex and BMI were signiﬁcant for presence of
active disease, number of respiratory symptoms and number of
asthmamedications used in the multivariable analyses, suggesting
that these associations were different between men and women.
Additionally, among pre-menopausal womenwith asthma, similar
effects were seen as among all women with asthma.
NEITHER SERUM ADIPONECTIN NOR BMI IS ASSOCIATED WITH
CHANGE IN FEV1 AMONG PARTICIPANTS WITH ASTHMA
Neither serum adiponectin concentrations nor BMI at year 15
were associated with change in absolute FEV1 between years 10
and 20 in men or women with asthma (Tables 3 and 4). Addi-
tional adjustment for height and height2 in these models did not
change the results. The effects of year 10 BMI and of change in BMI
between years 10 and 15 on the change in absolute FEV1 were also
separately explored, and results were similar to those described
above using year 15 BMI levels. Among pre-menopausal women
with asthma, similar effects were seen as among all women.
ALTERNATIVE ANALYTIC STRATEGIES
Additional adjustment for atopic status (deﬁned by the presence of
hay fever) at baseline (CARDIA year 0) examination did not affect
the results. Data on atopic status at year 15 examination were not
collected. The analysis was also rerun among those participants
at year 15 examination who ever noted wheezing, as opposed to
asthma as deﬁned previously (n = 930; 386men; and 544women);
the results were unchanged. The analysis was then rerun for sub-
jects with active asthma only (n = 77 men and 171 women); the
direction of associations was similar to that described in Tables 2
and 4 but many of the associations lost statistical signiﬁcance due
to reduced sample size. We evaluated the associations of change
in absolute FEV1 on serum adiponectin in Table 2 and on BMI in
Table 4 after addingbothheight andheight2 in the adjustedmodels
and found similar results as above. Similarly, adding inhaled cor-
ticosteroid use to the adjusted models did not affect the results.
Finally, the use of waist circumference instead of BMI in the
adjusted models did not affect the change in FEV1 results.
DISCUSSION
In this study, higher serum adiponectin concentrations may be
associated with adverse clinical outcomes of disease only among
men with asthma. Additionally, BMI may be associated with
adverse clinical outcomes of disease only among women with
asthma. The association of serum adiponectin with adverse clini-
cal outcomes of asthma in men is interestingly in contrast to our
previously reported ﬁndings that serum adiponectin may be asso-
ciated with decreased prevalence of asthma in women (Sood et al.,
2008) as well as to murine studies showing attenuation of air-
way hyperreactivity and eosinophilic inﬂux by adiponectin (Shore
et al., 2006). Taking these studies together, our data suggest that the
mechanisms of the associations between obesity, adipokines and
asthma are complex and are different between men and women.
Further, the ﬁndings from the mouse model (Shore et al., 2006)
may not be easily translated to humans and particularly men.
We conﬁrm our cross-sectional results in Table 2 by per-
forming additional longitudinal analyses in Table 3 that suggest
that greater serum adiponectin concentrations may worsen the
clinical outcomes of asthma among men and not vice versa. Fur-
ther conﬁrmation of the temporal sequence was provided by our
previously published study that showed that serum adiponectin
concentrations were unaffected by inhaled allergen-induced bron-
choprovocation in sensitized subjects with asthma (Sood et al.,
2009). Further, we did not ﬁnd either prevalent asthma or inhaled
corticosteroid use at year 10 examination in the CARDIA study
to predict serum adiponectin concentration at year 15. This sug-
gests that there are no acute or chronic effects of asthma on serum
adiponectin concentrations.
Although counter-intuitive, there are various explanations for
the possibly adverse effects of serum adiponectin on clinical
asthmaoutcomes inmen.Theremaybe a gender-relateddifference
in asthma phenotype that may explain our ﬁndings. There may be
a threshold above which serum adiponectin may have no effect
on asthma – concentrations in men usually fall below that thresh-
old and thus demonstrate an association whereas those in women
usually fall above that threshold and demonstrate no association.
Of note, our graphic exploration of data did not however suggest
such a non-linear association. Further, systemic testosterone may
either blunt the anti-inﬂammatory airway effect of adiponectin
or augment its little-known pro-inﬂammatory effect. The high-
molecular weight (HMW) isoform of systemic adiponectin may
be the beneﬁcial form for asthma, which is disproportionately
reduced in men as compared to women (Page et al., 2005;
Andersen et al., 2007). Finally, lungs in men may have receptor-
mediated resistance to the beneﬁcial effects of adiponectin. It
should be noted that the sex-related differences in adiponectin’s
anti-inﬂammatory function have been similarly described in pre-
vious studies of markers of cardiovascular disease (Lawlor et al.,
2005; Onat et al., 2008). If it is true that greater serum adiponectin
concentrations worsen clinical control/severity of disease among
men with asthma, pharmacologic measures to “blindly” increase
concentrations of all isoforms of serum adiponectin in future
clinical trials may in fact be harmful among men with asthma.
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Interestingly, a recent study of 14-year old boys by Kattan
et al. (2010) showed that greater systemic adiponectin was asso-
ciated with better asthma control, opposite of what we describe
in middle-aged men. It is possible that these conﬂicting results
may be explained by testosterone-related change in adiponectin
isoform distribution (toward a lower proportion of HMW iso-
form) that occurs in men (Page et al., 2005; Andersen et al., 2007).
Recent studies suggest that the HMW isoform is the most biolog-
ically active form of adiponectin in regulating insulin resistance
(Hara et al., 2006). Whether the same is true for asthma is not
known but the airway preponderance of the HMW isoform in
mice suggests that may be the case (Zhu et al., 2010). The study by
Kattan et al. (2010) also differed fromours in its use of clinic-based
recruitment; exclusion of mild asthma; and lack of multivariable
analyses and of longitudinal pulmonary function data.
A New Zealand-based birth cohort study (Sutherland et al.,
2009b) showed that serum adiponectin concentrations were nega-
tively correlated with fractional exhaled nitric oxide levels among
men (−0.16; 95% CI− 0.29, −0.04; p = 0.009) in an adjusted
analysis. Of note, these data included both men with and without
asthma diagnosis. Our study, on the other hand, was restricted
to those with asthma diagnosis alone and did not measure
exhaled nitric oxide levels. Further, Sutherland’s unadjusted analy-
sis showed that high serum adiponectin concentrations were
associated with greater, not lower odds for prevalent reversible
airﬂow obstruction among men. The latter data suggest a pro-
inﬂammatory effect of adiponectin in men and contradict the
exhaled nitric oxide data which suggest an anti-inﬂammatory
effect of adiponectin. Finally, unlike our study,Sutherland et al. did
not report signiﬁcant sex-speciﬁc interactions for asthma-related
outcomes.
Additionally, since adiponectin inhibits proliferation of vascu-
lar smooth muscle cells (Ouchi et al., 1999; Kondo et al., 2002;
Okamoto et al., 2002), it has been hypothesized that adiponectin
may inhibit airway smooth muscle proliferation (Shore, 2006),
thus improving airway remodeling in chronic asthma. Our study
however did not ﬁnd any signiﬁcant effect of serum adiponectin
on time-dependent decrease in FEV1. We therefore conclude that
it is unlikely that systemic adiponectin may improve in vivo air-
way remodeling in human asthma. This is consistent with recent
reports that adiponectin did not affect airway smoothmuscle pro-
liferation inmice or in vitro human experiments (Shin et al., 2008;
Medoff et al., 2009).
Prior studies of the association between obesity and asthma
outcomes have yielded conﬂicting results (Tantisira et al., 2003;
The Enfumosa StudyGroup, 2003;Wenzel andBusse, 2007;Mosen
et al., 2008; Taylor et al., 2008;Vortmann and Eisner, 2008; Suther-
land et al., 2009a). Our study demonstrates that obesity is asso-
ciated with adverse clinical outcomes of asthma but additionally
report these ﬁndings only in women. We further show that serum
adiponectin does not explain away the effect of obesity on clin-
ical outcomes of asthma in women, suggesting that the effect of
obesity may be mediated via multiple pathways including both
mechanical and inﬂammatory.
The strengths of our study include its sex-speciﬁc stratiﬁed
analysis, well-deﬁned study population set within a cohort struc-
ture, and its clinical translational character, based on the recently
published data on the role of systemic adiponectin in mouse and
human asthma (Shore, 2006; Shore et al., 2006; Sood et al., 2008;
Nagel et al., 2009). Further, the results from our cross-sectional
analyses are supported by our longitudinal analyses. Another
unique feature of our study is its community-based, rather than
clinic-based recruitment.
The study however, has several limitations. One signiﬁcant lim-
itation is the use of self-report of provider-diagnosed asthma.
However, self-report is the standard deﬁnition used in epidemi-
ological studies, despite the misclassiﬁcation bias relative to the
“gold standard”of airway hyperresponsiveness (Aaron et al., 2008).
Although asthma misclassiﬁcation has not been studied with
respect to adiponectin, this misclassiﬁcation is non-differential
between obese and non-obese subjects (Appleton et al., 2006;
Aaron et al., 2008; Lang et al., 2009). With non-differential mis-
classiﬁcation errors, the bias is typically in a predictable direction
(i.e., toward lack of association) and unlikely to produce a spu-
rious effect. Additionally, self-report may miss subjects with mild
asthma severity. However, this is unlikely, given that most subjects
in our community-based study were of mild intermittent severity,
as suggested by their relatively low rates of inhaled corticosteroid
use shown in Table 1 (National Heart Lung and Blood Insti-
tute, 2007a). This distribution is however consistent with another
community-based study where intermittent disease was also the
most prevalent asthma type (Fuhlbrigge et al., 2002). Not surpris-
ingly, the proportion of subjects with moderate or severe asthma
in our study was smaller than most clinic-based studies – this
may affect the generalizability of our ﬁndings. We cannot entirely
rule out the possibility of the misdiagnosis of chronic obstruc-
tive pulmonary disease (COPD) subjects as asthma in our study.
However, this possibility is less likely given the relatively young
age of subjects (40.2± 3.6 years); high proportion of never smok-
ers (59.3%); and rare use of anti-muscarinic inhaler drugs (two
subjects using ipratropium and another four using ipratropium–
albuterol combination) at CARDIA year 15 examination as well
as the high levels of year 10 mean prebronchodilator FEV1/FVC
ratio (76.8± 8.1%). Further, we do adjust for smoking behavior,
the most important risk factor for COPD, without affecting our
results. Further, current deﬁnitions of asthma control/severity are
less than ideal, particularly for population research (Ungar et al.,
2002; Reddel et al., 2009). Although it is reasonable to study med-
ication use as a measure of asthma control/severity (Cockcroft
and Swystun, 1996), our assumption that the need for asthma
medication can be equated with report of taking the medica-
tion may not be entirely true. The lowest dose of maintenance
inhaled corticosteroids required after asthma control is achieved,
a key measure in assessing clinical disease severity among treated
patients (National Heart Lung and Blood Institute, 2007a,b), was
not available in this population study. Additionally, data assessing
symptomatic asthma control using standardized asthma question-
naires were not collected in this population study. On the other
hand, we analyzed a number of respiratory symptoms that may be
relevant for several cardiopulmonary conditions including asthma
and systemic conditions including obesity. It should nevertheless
be pointed out that there were no cases with clinical atheroscle-
rotic cardiovascular disease among the 411 subjects studied at year
15 and that we adjusted for obesity in our models. Longitudinal
www.frontiersin.org October 2011 | Volume 2 | Article 55 | 9
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analysis of the effect of year 15 serum adiponectin on subsequent
change in lung function requires the baseline lung function to be
assessed at year 15. Unfortunately, spirometry was not performed
at CARDIA year 15 examination and therefore spirometry at year
10 was instead used as baseline (Figure 2).
Selection bias may occur if subjects with adiponectin measure-
ments were not representative of the total asthma population.
However, we found that subjects with asthma with or without
adiponectin measurements did not differ with respect to either
obesity or asthma outcomes measures (data not shown). Further,
data on atopy were not collected at CARDIA year 15 examina-
tion. However, adjustment for self-reported atopic status at year
0 examination did not affect the results. This study did not mea-
sure the serum concentrations of various isoforms of adiponectin,
other adipokines, or reproductive hormones. It is possible that the
various isoforms have varying in vivo activity for asthma. It is also
not clear whether there is a correlation between serum and airway
concentrations of total adiponectin and its isoforms. Further, a
single assessment of a biomarker may be susceptible to short-term
variation and may not reﬂect long-term exposure. However, stud-
ies suggest that serum concentrations of adiponectin are stable
(Pischon et al., 2003; Lukanova et al., 2006; Kaplan et al., 2007)
and therefore, it is a good candidate for long-term risk assessment.
Our data in Table 2 are cross-sectional which limits our ability
to infer causality. However, the cross-sectional ﬁndings are sup-
ported by longitudinal data in Table 3 that allow for inference of
the direction of association. It is still however premature to con-
clude a causal association between serum adiponectin and asthma
control/severity.
In summary, our study of predominantly mild asthma from
a community-based middle-aged population shows that systemic
adiponectin concentrations may have opposing associations with
clinical control/severity outcomes of asthma between men and
women. Among men with asthma, higher systemic adiponectin
concentrations may adversely affect clinical outcomes of disease.
Future studies involving the modiﬁcation of systemic adiponectin
concentrations may open up newer ways to treat asthma in men.
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